ºû¥Í¯ÀE¼vÅT®a¸Vªº¬¡¤O¤Î§K¬Ì¤ÏÀ³
¤ý¥¿´Ü
´f³Ó·»¾¯´£ªo¼tªÑ¥÷¦³¤½¥q
¡@¡@ºû¥Í¯À E ¬OÀu¨}ªº®a¸VÀç¾i¤§¥²»Ýn¯À¡CµM¦Ó¡A¥¦ªº¯u¥¿«n©Ê«oÂA¬°¤Hª¾¡C¥»¤å¤D¦b±´°Q¡G(1)¨j¹å¤ÆªºÂúÂû¤§¬¡¤O¡A(2)ÂúÂû©è§Ü¶Ç¬V©Ê¯e¯fªº¤ÏÀ³¡A(3)ºû¥Í¯À E¡BÖ´ ( Se ) »P§K¬Ì¤TªÌªº¬Û¤¬Ãö«Y¡A(4)ºò¢ªº®ÄÀ³¡A¥H¤Î (5)ºû¥Í¯À E §êºtªº¨¤¦â¡C
¤Þ¡@¡@¨¥
¡@¡@³\¦h¤£¦Pªº«OÅ@¾÷¨î¤w¸g³Q¯Ç¤J¦b®a¸V¥Í³Jp¹ºªº½d³ò¤¤¡A¦Ó¥B½T«OFL¨ì¹å¤Æ®É±o¥H¦s¬¡ªº¾÷¨î¤]³Q¬ã¨s¡CRomanff ¤À§O¦b 1949 ¦~¤Î 1972 ¦~µoªí¤F¦³Ãö¥Û¦Ç½èªº³J´ß¤Î³J´ß½¤¯à°÷±Æ°£·L¥Íª«ªº«I¤J¡A¥H¤Î³J¥Õ·|ªý¤î·L¥Íª«ªº¥Íªø¡C¦Ó 1961 ¦~ Kent¡A1963 ¦~ Karthigasu & Jenkin¡A1964 ¦~ Karthigasu µ¥¤H¡A1966 ¦~ Solomon ¤Î 1973 ¦~ Mizejewski µ¥¤H¡A¥ý«á¬ã¨s¥X¦å²G¤¤¤j¶qªº¬y°Ê¥Õ¦å²y ( Leucocytes ) ©Mºôª¬¤º¥Ö¨t²Î ( Reticuloendothelial system ²ºÙ RES ) ¤¤ªº¥¨¾½²ÓM ( macrophages ) ²Õ¦¨¤F¤@ºØ«D¯S²§©Êªº²ÓM©Ê¨¾¿m¾÷ºc ( nonspecific cellular defense ) ¨Ó²M°£¦Ñ¤Æ²ÓMªºFL©M¥~¨Óª«½è¡C³oºØ«OÅ@¾÷¨î·|¦]¤zÂZ¤¸ ( interferon )¡A¸ÉÅé ( complement )¡A½Õ²z¯À ( opsonins ) ©M¥À©Ê§ÜÅé ( maternal antibodies ) ªº¥X²{¦Ó¥[±j¨ä¾÷¨î¬¡©Ê¡C
¡@
(¤@)®a¸Vªº§K¬Ì¨t²Î
¡@¡@Glick ¦b 1977 ¦~¤Î 1978 ¦~¡A¦Ó 1979 ¦~ Shields µ¥¤H¤Î 1980 ¦~ Kendaal ³£³°³°ÄòÄòÃÒ¹ê¤F¡A§K¬Ì¨t²Î ( the immune system ) ªºµo¨|¬O¤@Ó½ÆÂø¡B¯A¤Î¼sªxªº¹Lµ{¡A¥¦¥]¬A¤Fªì¯Å²O¤Ú²Õ´©M¦¸¯Å²O¤Ú²Õ´ªº¦X¨Öµo¨| ( concurrent development )¡A¥H¤Î¥]²[¤F¤£¦P²O¤Ú®É´Áªº¼W¥Í»P¤À¤Æ¤§²O¤Ú¥ý½è²ÓM ( Lymphoid progenitor cells ) ªº§Î¦¨¡CFÅé¥~ªº§Z¶ÀÅn ( extra - embryonic yolk sac. ) ©MFÅ餺ªº³y¦å¾÷ºc ( intra - embryonic hemopoietic sites ) ²£¥Í¤F¦h·¥©Êªº¦å¤¤ºØì²ÓM ( multipotential blood stem cells )¡AµM«á²¾¥X¨Ã´å¨«¨ì¥¿¦bµo¨|ªº¯Ý¸¢ ( thymus )¡B·Æ¤óÅn ( bursa of Fabricius )¡BµÊŦ ( spleen )¡B°©Åè ( bone marrow )¤Î¨ä¥L¥¼¨Óªº³y¦å²Õ´¤§°òÅé ( rudiments )¡C¹Ï¤@Åã¥Ü¥X®a¸V§K¬Ì¨t²Îªº¦´Áµo¨|¡C¥]¬A¤F¤TÓ¶¥¬q¡G
(1)·L¤pÀô¹Òªºµo¨| ( Development of microenvironment )¡F
(2)²O¤Ú²ÓMªº¥Í¦¨ ( Lymphocytogenesis )¡F
(3)¥\¯à¬Û ( Functional phase )¡C
¡@
¡@
¡@¡@¦b¯Ý¸¢ªº·L¤pÀô¹Ò¤¤¡A²O¤Ú¥ý½è²ÓM¥ý¶i¦æ³s¦X ( committed )¡A¦A¸g¥Ñ T ²ÓM¶i¤@¨Bªº¼W¥Í¡B¤À¤Æ¡A¹F¦¨²ÓM¤¤¶¡©Ê§K¬Ìªº¥\¯à ( Cell - medium immune functions )¡C¦Ó¥t¥~¤@¨ÇºØì²ÓM ( s - cell ) ¶i¤J·Æ¤óÅn¤¤¡A¼W¥Í¡B¤À¤Æ¦¨ B ²ÓM¦X¦¨ªÌ¡V¡V§K¬Ì²y³J¥Õ ( Ig ) ªº¤£¦P«¬¦¡¦P·½ª«½è ( clones )¡V¡VÅé²G§K¬Ì ( humoral immunity ) ªº¨ü°Ê¾¹²ÓM ( effector cells )¡CT ²ÓM©M B ²ÓMÂ÷¶}¤Fªì¯Å²O¤Ú¤W¥Ö¾¹©x ( lymphoepithelial organs )¡A´å¨«¨ìµÊŦ©M¦¸¯Å²O¤Ú²Õ´¤¤¡A¶i¦æ§ó¶i¤@¨Bªº¤À¤Æ©MÀò±o§Üì ( antigen ) ¤ÏÀ³ªº¯à¤O¡C¤@¥¹±Á{§Y±N¹å¤Æ¤§»Ú¡A¥~³ò²O¤Ú²Õ´ ( Peripheral lymphoid ) ¤¤±M¥q§K¬Ì¤Î¨ä¥LªþÄݪº²ÓM¼Æ¥Ø¡A¨ì¹F¤@ÓìHÈ ( threshold level ) ®É¡A§K¬Ì¯à¤O´N·|«Ü®e©ö¦aªí²{¥X¨Ó¡C
¡@
(¤G)ºû¥Í¯À E ªº¥À©Ê²¾§Î ( maternal carry - over ) »P¤pÂûªº§K¬Ì
¡@¡@³Ìªñ¦³¤@¨Ç¬ã¨s³ø§i«ü¥X¡Aºû¥Í¯À E ¹ï¤pÂûªº§K¬Ì¨t²Î¡A¬O¤@ºØ¦³®Äªº¨ë¿E¯À¡C¹}³¤¤´£°ªºû¥Í¯À E ªº³B²z¡A¥i¥H¼W¥[¤pÂûªº§K¬Ì¤ÏÀ³¡A¤]¼W¥[¤F¹ï¤j¸z±ìµß ( Escherichia coli ) «I¥Çªº©è§Ü¤O¡C
¡@¡@1952 ¦~ Buxton¡B1971 ¦~ Gaultney µ¥¤H³£¥Ñ¸ÕÅç¬ã¨s±o¨ì¥H¤Uªºµ²½×¡A¨º´N¬O¤pÂûªº§ÜÅé¡A¬O¥ÀÂû¸g§Z¶ÀÅn¡A¥H³Q°Ê¹B¿é ( passively transfer ) ¶Çµ¹¤pÂûªº¡C
¡@¡@1978 ¦~ Jackson µ¥¤H¡A¤]±o¨ì¬Û¦Pªºµ²½×¡A¥Ḻq¸ÕÅ礤±oª¾¡A·í¹}³¤¤²K¥[ 150 ©M 450 ²@§J¡þ¤½¤çºû¥Í¯À E¡AÁý¹}¥ÀÂû¥i¥H¹ï¥¬¤ó¬y²£±ìµß ( Brucella abortus ) ¦³«Ü¦nªº§K¬Ì§@¥Î¤§®É¡A¤]¹ï 2 ¤éÄÖ©M 7 ¤éÄÖ¤pÂû¦å¼ß¤¤¡A¸g¥Ñ³Q°Ê¹B¿éªº²¾§Î§ÜÅ馳ÅãµÛ¼W¥[ªºÁͶաCµM¦Ó¡A°²¦p¥H 90¡B300 ¤Î 900 ²@§J¡þ¤½¤çºû¥Í¯À E ªº¹}³Áý¹}¥¼¨ã§K¬Ì§@¥Îªº¥ÀÂû¡A«h¤pÂû±o¤£¨ì¸û¨Îªº§ÜÅé»ù ( ant ibody titers )¡C©Ò¥H¡A¥H¾A·í¿@«×ªººû¥Í¯À E ²K¥[¡AÁý¹}¤w¨ã§K¬Ì§@¥Îªº¥ÀÂû¡A¥i¥H§ïµ½¤pÂûªº§ÜÅé»ù¨Ã½á¤©¸û¨Îªº«OÅ@§@¥Î¡C
¡@¡@1979 ¦~ Nockels ¤]´£¥X¸ò Jackson ¬ÛÃþ¦üµ²ªGªº³ø§i¡Aªí¥Ü¥ÀÂû¹}Áý 150 ©Î 450 IU¡þ¤½¤çºû¥Í¯À E ªº¹}³®É¡A2 ¤éÄÖ©M 7 ¤éÄÖªº¤pÂû¦³©úÅã´£°ª§ÜÅé§t¶qªº¶É¦V¡A( P<0.01 )¡C¦Ó¥B 7 ¤éÄÖªº¤pÂû¤ñ 2 ¤éÄÖªº¤pÂû§t¦³¸û§C¶qªº§ÜÅé»ù¡A( P<0.01 ) ( ¨£ªí 1 )¡C¥ÀÂûÁý¹}¤£¦P§t¶qªººû¥Í¯À E¡A¤Ï¬M¦b¤pÂûªº¥Íª«¬Û¤§§ÜÅé¤ÏÀ³ ( biophasic ant ibody response ) ¤è±¡C
¡@
ªí 1. ¥ÀÂûÁý¹}ºû¥Í¯À E¡A¹ï¤pÂû³Q°Ê¦aÀò±o§K¬Ì§@¥Îªº®ÄÀ³ a
¥À ©Ê ¤¤ ºû¥Í¯À E ¤§§t¶q ¼W²K¶q IU¡þ¤½¤ç |
2 ¤é ÄÖ | 7 ¤é ÄÖ | ||
¤p Âû ¼Æ ¥Ø |
¾®¶°¯À»ùb log2 |
¤p Âû ¼Æ ¥Ø |
¾®¶°¯À»ù log2 |
|
0 90 150 300 450 900 |
26 31 22 20 21 14 |
2.68 Ac 2.94 ABC 3.18 BC 2.59 A 3.34 C 2.79 A |
50 62 38 40 40 31 |
2.16 A 2.18 A 2.65 B 2.12 A 2.62 B 2.19 A |
a¡B¥ÀÂû¦b¹å³J¤§«e¥|¬P´Á¡A¤w¸g¥H¥¬¤ó¬y²£±ìµß¹ê¬I¦Ù¦×§K¬Ì ( immunized intramuscularly )¡C
b¡B¥»³B²z¤¤ 2 ¤éÄ֤Π7 ¤éÄÖªº¾®¶°¯À»ù¤£ºÉ¬Û¦P ( P<0.01 )¡C
c¡B¥§¡È«á¤£¦Pªº^¤å¤j¼g¦r¥À¡Aªí¥Ü®t²§ÅãµÛ ( P<0.01 )¡C
¡@
¡@¡@Nockels ¤S°µ¤F²K¥[ 6 ºØ§t¶q¤§ºû¥Í¯À E ªº¤é³¡AÁý¹}¨S¦³§K¬Ì§@¥Îªº¥ÀÂû¡A¹ï¤pÂû§K¬Ì¤ÏÀ³ªº¼vÅT¤§¸ÕÅç¡A¥L±o¨ì¤@¨Çµ²½×¡Aµ²½×¬O¨S¦³³Q§K¬Ìªº¤pÂû¡A´N¨S¦³©úÅ㪺§ÜÅé»ù¡C¥u¦³±qÁý¹} 450 IU¡þ¤½¤çºû¥Í¯À E ¹}³ªº¥ÀÂû©Ò²£¥Íªº³Q§K¬Ìªº 21 ¤éÄÖ©M 28 ¤éÄÖ¤pÂû¡A¤~¦³¤ñ¹ï·Ó²Õ§óÅãµÛ¼W¥[ªº¾®¶°¯À»ù ( agglutinin titers ) ¥X²{¡A( ¤À§O¬OP<0.01 ¤Î P<0.05 ) ( ¨£ªí 2 )¡C¦Ó¥B¡A³o¥i¥H¤Ï¬M¥X¥Ñ¥ÀÂûªººû¥Í¯À E Âಾ¨ì¤pÂûªººôª¬¤º¥Ö¨t²Î ( RES ) ¤§¥Íª«¬Û¤ÏÀ³¡C
ªí 2. ¥¼¨ü§K¬Ìªº¥ÀÂû¹}Áýºû¥Í¯À E¡A¹ï¤pÂû³Ìªìªº§K¬Ì¤ÏÀ³¤§®ÄÀ³
¥À ©Ê ¤è
± ºû¥Í¯À E ªº²K ¥[¶q IU¡þ¤½¤ç |
21 ¤é ÄÖ | 28 ¤é ÄÖ | ||
¤p Âû ¼Æ ¥Ø |
¾®¶°¯À»ù¹ï ¼ÆÈ log2 |
¤p Âû ¼Æ ¥Ø |
¾®¶°¯À»ù¹ï ¼ÆÈ log2 |
|
0 90 150 300 450 900 |
49 33 48 34 33 46 |
3.96 A 4.47 AB 4.07 A 3.85 A 4.91 B 4.13 A |
44 31 47 36 31 41 |
5.72 a 5.44 a 5.61 a 5.94 a 6.37 b 5.90 a |
µù¡G(1)¤pÂû©ó 14 ¤éÄ֮ɡA¹ê¬I¥¬¤ó¬y²£±ìµß¤§¦Ù¦×§K¬Ì¡C
(2)¥»³B²z©ó 21©M 28¤éÄֱĦå´ú¦å²y¾®¶°»ù¡C
(3)¥§¡È«á¤£¦Pªº^¤å¦r¥À¤j¼g¡Aªí¥Ü®t²§ªºÅãµÛ©Ê ( P<0.01 )¡C¦Ó¤p¼g¦r¥Àªí P<0.05 ªº®t²§ÅãµÛ©Ê¡C
(4)¸ê®Æ¨Ó·½¡GNockels ( 1979 )¡C
¡@
(¤T)ºû¥Í¯À E ©M¶Ç¬V©Ê¯e¯fªº©è§Ü¤O
¡@¡@ÁöµM¤w¸gª¾¹Dºû¥Í¯À E ¥i¥H¨ë¿E§ÜÅé¤ÏÀ³¡A¦ý¬O³o¨Ã¤£·N¨ýµÛ¤@©w¥i¥H¦Ê¤À¤§¦Ê¦a§ïµ½¯e¯fªº©è§Ü¤O¡C©ó¬O¡A¦³¨Ç±M®a´NµÛ¤â¤@¨t¦Cªº¬ã¨s¡A¬ã¨s°²¨Ï²K¥[¹L¶qªººû¥Í¯À E¡A¹ï¥¿±`¥Íªøªº»Ý¨D©M¯à§_²£¥Í°Êª«¬Y¨Ç¯fì ( Pathogens ) ªº©è§Ü¤Oªº®ÄÀ³¡C
¡@¡@®Ú¾Ú«Ü¦h¬ã¨s³ø§i«ü¥X¡Aºû¥Í¯À E ªº¯Ê¥F¡A¨Ã¤£·|¾ÉP§K¬Ì¤ÏÀ³ªº¶Ë®`¡CµM¦Ó¡A¥t¤@¤è±¤]¦³±M®a̤@P»{¬°¨Ï¥Î¹L¶qªººû¥Í¯À E¡A¥i¥H¹ï§ÜÅ骺²£¥Í¦³¨ë¿E©Êªº¼vÅT¡A¤×¨ä¬O§K¬Ì²y³J¥Õ G ( IgG ) ªº²£¥Í¡C¤ä«ù³o¨Ç½×ÂIªº±M®a§ó¶i¤@¨B´£¥X¡A¨Ï¥Îºû¥Í¯À E ¥i¥H¼W¶iºôª¬¤º¥Ö¨t²Î ( RES ) ªº§]¾½§@¥Î¤§¬¡©Ê¡A¼W¥[µÊŦªº«¶q¡A¥H¤ÎµÊŦ¤º²£¥Í§ÜÅ骺²ÓM¼Æ¥Ø¤]·|¼W¥[¡C
¡@¡@ºû¥Í¯À E ¦ü¥G¥i¥HÂǵۼW¥[ Ubiquinones ªº¦X¦¨¡A¨Ó¨ë¿E¨¾¿m¾÷¨î¡A¦]¬° Ubiquinones ¯à°÷¼W¥[ºôª¬¤º¥Ö¨t²Î ( RES ) ªº§]¾½§@¥Î¤§¬¡©Ê¡Cºû¥Í¯À E ªº«OÅ@®Ä¯ànÂk¥\©ó¨âÓ¥Dnªº¦]¤l¡Ga. Åé²G§K¬Ìªº´£°ª¡A©M b. §]¾½§@¥Îªº¨ë¿E¡C
¡@¡@µL½×¦b¸ÕºÞ¤º©Î¦b¬¡Å餺¸ÕÅç¡Aºû¥Í¯À E ³£¥i¥H´£°ª¦Ñ¹«©M¤pÂûªº§ÜÅé§Î¦¨²ÓM ( §Y¦å¤pªO Plaque §Î¦¨²ÓM ) ¤§¼Æ¥Ø¡A¦Ó¥B´£°ª§K¬Ì²y³J¥Õ G ( IgG ) ©M§K¬Ì²y³J¥Õ M ( IgM ) ªº§ÜÅé»ù¡Cºû¥Í¯À E ¤]´£°ª¤F¯S²§©ÊÅé²G§K¬Ì¤ÏÀ³©M²ÓM¤¤¶¡©Ê§K¬Ì¤ÏÀ³¡A´N¹³¬O¥»¯à©Êªº©è§Ü¯e¯f¡A¯S§O¬O§]¾½§@¥Î¡C
¡@¡@1981 ¦~ Tengerdy µ¥¤H»{¬°ºû¥Í¯À E ¨Ï¥Î¨ì¤ñ²{¦æ¥Í²£ªº¹}³§t¶q°ª 3 ~ 6 ¿ªº¾¯¶q¡A©Î¹³¨C¤é±ÀÂ˶qªºÃľ¯®É¡A¬O«Ü¦³®Ä²vªº¡Cºû¥Í¯À E §@¥Î¤§¾÷¨î¥]¬A¤F (1)¤@¯ë©Êªº§Ü®ñ¤Æ¾¯®ÄÀ³ ( General antioxidant effect )¡A¥i¥Hªý¤î¹L®ñ¤Æ§@¥Î ( Peroxidation ) ©Mªý¼¸¦Û¥Ñ°ò ( Free radical ) ¶Ë®`¨ì±Ó·Pªº²O¤Ú¤W¥Ö²ÓM ( Lymphoreticular cells )¡F(2)¯S²§©Êªº§Ü®ñ¤Æ¾¯®ÄÀ³ ( Specific antioxiolant effect )¡A¦b©óÂǵ۪ý¤î L - arachidonic acid ªº®ñ¤Æ§@¥Î¡A©M¼vÅT®ñ¤ÆÁC»Ä¤Æ ( Oxidative phosphorylation ) §@¥ÎªºÃöÁä»Ã¯À ( Key enzyme )¡A¨Ò¦p¤zÂZ»²úA Q ( Coenzyme Q ) ©M²ÓM¦â¯À ( Cytochrome ) ªº¥Í¦X¦¨¡A¦Ó¥B¤]ÂǵۧïÅܲO¤Ú²ÓMªº²ÓM½¤¤§·P¨ü¾¹¥\¯à ( Receptor function )¡A¨Ó§í¨î«e¦C¸¢¯Àªº¥Í¦X¦¨¤ÏÀ³¡C
¡@¡@
(¥|)¤pÂû¹ï¤j¸z±ìµß ( E. Coli ) ªº¤ÏÀ³
¡@¡@1974 ¦~ Heinzerling µ¥¤H«ü¥X¡A·í¤pÂû©M¤õÂû·P¬V¤j¸z±ìµß ( Escherichia coli ) ®É¡AÁý¹}²K¥[ºû¥Í¯À E ¹}³¡A¥i¥H°§C¦º¤`²v©M¼W¥[¦å²y¾®¶°¤ÏÀ³»ù ( hemo - agglutination ( HA ) reaction titers )¡C³o¨Çµ²ªG¥¿¦pªí 3¡A¤GÓ¸ÕÅ礤©ÒÅã¥Üªº¡AÁý¹}®Æ²K¥[ 150 ©Î 300 IU¡þ¤½¤çºû¥Í¯À E ªº¹}³¡A½T¹ê¥i¥H«ÜÅãµÛ¦a°§C¦º¤`²v ( P<0.01 )¡C¦Ó¥B¸ÕÅç 1 ¤¤Åã¥Ü¥X¡Aºû¥Í¯À E ¹ï¤G¶gÄÖ¤pÂûªºÅé¼W«¦³©úÅã¦Ó¦³§Qªº¼vÅT ( P<0.01 )¡A¦ý¸ÕÅç 2 «hµL¦¹²{¶H¡C
ªí 3 ¤w·P¬V¤j¸z±ìµßªº¤pÂû¡Aºû¥Í¯À E ¹ï¨ä¥Íªø¡B¦º¤`²v¡B
¦å²y¾®¶°»ù©M¦å²M²y³J¥Õ¤ñ²v
ºû¥Í¯À E ²K ¥[ ¶q IU¡þ¤½¤ç |
¤p Âû ¼Æ ¥Ø |
¦º¤`²v | 2 ~ 4 ¶g ¥§¡¼W« ( §J ) |
¦å²y¾®¶° »ù¹ï¼ÆÈ log2 |
¦å²M²y³J¥Õ¤ñ²v¡A% | |||
£\1 | £\2 | £]1 | £^1 | |||||
¸Õ Åç ¤@ | ||||||||
0 150 300 |
36 34 37 |
25.0 B 9.3 A 5.4 A |
284 B 313 A 330 A |
7.75 B 10.75 A 10.00 A |
4.9 a 4.0 a 3.7 a |
12.2 a 13.3 b 15.5 b |
16.0 a 12.8 b 11.8 b |
18.9 a 19.0 a 20.7 a |
¸Õ Åç ¤G | ||||||||
0 150 300 |
42 40 40 |
31.0 B 4.9 A 0.0 A |
395 A 367 A 387 A |
6.66 B 8.83 A 9.66 A |
2.8 a 4.8 a 3.4 a |
13.5 a 19.3 a 16.1 b |
14.5 a 12.3 a 11.9 b |
16.9 a 18.9 a 17.7 a |
µù¡G(1)¤pÂû©ó 15 ¤éÄ֮ɡA¦b«á¯Ý³¡®ðÅn±µºØ¤j¸z±ìµß¡F©ó 29 ¤éÄÖ¤§¤pÂû±Ä¦å´ú¦å²y¾®¶°»ù¡C¦Ó¦å²M²y³J¥Õªº¤ñ²v¡A¸ÕÅç¤@¤¤¥H¨C³B²z²Õ 4 °¦¤p Âû¨Ó´ú©w¡A¸ÕÅç¤G¤¤¥H¨C³B²z²Õ 5 °¦¤pÂû¨Ó´ú©w¡C
(2)¥§¡È«á±ªº¤j¼g¦r¥À¡A¥Nªí P<0.01 ®Éªº®t²§ÅãµÛ©Ê¥§¡È«á±ªº¤p¼g¦r¥À¡A¥Nªí P<0.05 ®Éªº®t²§ÅãµÛ©Ê
(3)¸ê®Æ¨Ó·½¡GHeinzerling µ¥¤H ( 1974 )
¡@
¡@¡@³o¤GÓ¸ÕÅç©Ò²£¥ÍÅé¼W«ªº®t²§¡A¥i¯àªº¸ÑÄÀ¬O¦º¤`²vªº¤£¦P©Ò¾ÉPªº¡C¸ÕÅç¤@¤¤¡A¦]¬°³Q·P¬VÂû°¦ªº«ì´_±¡§Î¡A¥¿¦p¬¡ÂûÅé¼W«°§C±¡§Î¤@¼Ë¦a©úÅã¡A©Ò¥H¦³¸û¤Öªº³Q·P¬V¤pÂûµo¥Í¦º¤`¡C¦b¥¼¨ü·P¬Vªº±±¨î²Õ¤¤¡AµÊŦ©M·Æ¤óÅnªº«¶q´N¹³Å髪º¦Ê¤À¤ñ¡A¨S¦³¦]ºû¥Í¯À E ªº²K¥[¦Ó¦³©Ò§ïÅÜ¡C¤£ºÞ¦p¦ó¡A¦bµÊŦ«¶q¤è±¡A²K¥[ºû¥Í¯À E »P¤£²K¥[ºû¥Í¯À E¡A³£¨S¦³ÅãµÛ®t²§¡C
¡@¡@·í¨ü·P¬Vªº¤pÂû¼W¥[ºû¥Í¯À E ªº²K¥[¶q¡A¥i¥HÅãµÛ¦a¼W¥[¦å²y¾®¶°§ÜÅé»ù¡A¦Ó¥B¹ï©ó¦º¤`²v°§C¤]¦³¬Û¦Pªºµ²ªG¡C¼W¥[¹}³¤¤ºû¥Í¯À E ªº§t¶q¡A¤]¾ÉP¤pÂû¹ï¤j¸z±ìµßªº£\¡V¦å²M²y³J¥Õ¤ñ²v ( £\¡VSerum globulin fraction ) ¤j¤j¦a´£°ª¡A( P<0.05 )¡C¦Ó¤£ºÞ¬O§_³Q·P¬V¡A²K¥[ºû¥Í¯À E ·|¨Ï £]¡V¦å²M²y³J¥Õ¤ñ²v ( beta - serum globulin fraction ) ÅãµÛ¦a°§C¡A( P<0.05 )¡C³o¨Çµ²ªG·t¥ÜµÛ¤pÂûÊï§Ü¤j¸z±ìµß·P¬Vªº«OÅ@¯à¤O¼W¥[¡A¥i¯à¬O¹}³¤¤²K¥[ºû¥Í¯À E¡A©Ò³y¦¨Åé²G©Ê§K¬Ì¤ÏÀ³´£°ªªº½t¬G¡C
¡@
(¤)¤pÂû¹ï²yÂίgªº¤ÏÀ³
¡@¡@1981 ¦~ March µ¥¤H«ü¥X¡A¤pÂû¹ïºû¥Í¯À E ©ÎÖ´ ( Se ) ªº¯Ê¥F±¡§Î¡A©Î¬O¦¹¤GªÌ¹ï§K¬Ì¥\¯àªº×Å@±¡§Î¡A¥i¥HÂǵ۹ï¦Ï¬õ¦å²y ( erythrocytes ) ªºÅé²G¤ÏÀ³´ú©w¥X¨Ó¡Cºû¥Í¯À E ©MÖ´ ( Se ) ªº¯Ê¥F¡A´î¤Ö¤F·Æ¤óÅnªº«¶q¡A¤]°§C¤Fªì¯Å²O¤Ú¾¹©x©MµÊŦ¤¤ªº²O¤Ú²y¤§Á`¼Æ¡A¦Ó¥B·|¤Þ°_³o¨Ç²Õ´¤º³¡§ïÅܪº¯}Ãa¡C
¡@¡@1984 ¦~ Colnago µ¥¤H±q¥|Ó¹êÅ礤±o¨ìµ²½×¡A·í¹}³¤¤²K¥[Ö´ ( Se ) 0.25 ²@§J¡þ¤½¤ç©Îºû¥Í¯À E 100 ²@§J¡þ¤½¤ç®É¡A¹ï¨S¦³³Q§K¬Ì¦Ó¨ü E - tenella ·P¬Vªº¤pÂû¡A·|°§C¨ä¦º¤`²v©M¼W¥[¨äÅé¼W«¡C¤]´N¬O»¡Ö´ ( Se ) ©Îºû¥Í¯À E ªº²K¥[¡A¹ï¤pÂû©è§Ü²y¤¤«Iŧªº§K¬Ì¯à¤O¦³¼W°ªªº§@¥Î¡C
¡@
(¤»)ºû¥Í¯À E¡BÖ´ ( Se ) ¤Î§K¬Ì
¡@¡@ºû¥Í¯À E ¬O¬¡¤Æ¦¸²ÓM½¤ ( vital subcellular membranes ) ¹ï§Ü¹L®ñ¤Æª«ªº¶Ë®`¤§²Ä¤@¹D¨¾½u¡CÖ´ ( Se ) «h¸g¥Ñ¾¢®ò°ò²¸¹L®ñ¤ÆúA ( glutathoine peroxides ) ªº§@¥Î¡A¯}Ãa¤F¥ô¦óÂǺû¥Í¯À E ¨¾¿m¾÷¨î©ÒÀò±oªº¹L®ñ¤Æª«¡A¦]¦¹¦³ªý¤î¹L®ñ¤Æª«µo¥Í³sÂê¤ÏÀ³¡B¯}Ãa¬¡¤Æ²B²¸°ò¤ÆúA ( vital sulfhydryl enyzmes )¡A¥H¤Î¶Ë®`¨ä¥L¦³Ãö§K©ó¯e¯f¦Óºû«ù°Êª«Àç¾i°·±d¥²»Ýªº¨t²Îµ¥¥\¯à¡C
¡@¡@ºû¥Í¯À E ©MÖ´ ( Se ) ªº¥\¯à¡A³Q»{¬°¦b©óºûÅ@¬õ¦å²y²ÓM½¤ ( erythrocyte membrane ) ¤§§¹¾ã©Ê¡C¥Ñ¹Ï¤G¤¤±oª¾¡A¬õ¦å²y²ÓM©M²O¤Ú²ÓM³£¬O°_·½©ó¤@¯ëªº¦h¥\¯à¤§ºØì²ÓM ( common pluripotential stem cells )¡A³oӨƹêÃÒ¹ê¤Fºû¥Í¯À E ©MÖ´ ( Se ) »P²O¤Ú²ÓMªº²ÓM½¤¬y³q©Ê ( membranes fluidity ) ¦³ÃöÁpªº·§©À°ò¦¡A¦]¦¹¥i¥H±Àª¾ºû¥Í¯À E¡BÖ´ ( Se ) ¹ï¼vÅT§K¬Ì¤ÏÀ³¾÷¨îªº§@¥Î¤]¬O¤@¼Ë¡C
¡@¡@±q 1972 ¦~¨ì 1977 ¦~ Tengerdy¡ASpallholz¡ABrown ¤Î Berber µ¥¤H¡A¤À§Oªº¬ã¨sµ²ªG¡A³£¤@P¤ä«ù¤Wzªº°²³]¡C¦b¥L̳̪쪺¬ã¨s¤¤¡A«ü¥X¤F¹}³¤¤ºû¥Í¯À E ¼W¥[¤¿®É¡A¤pÂû©è§Ü¦Ï¬õ¦å²yªºÅé²G©Ê§K¬Ì¤ÏÀ³·|¼W±j¡C¥L̤]»{¬°ºû¥Í¯À E ªº§K¬Ì¨ë¿E©Ê ( immunostimulation ) ¸ò¨ä§Ü®ñ¤Æ¾¯¤§§@¥Î¦³±K¤ÁÃö«Y¡C¦Ó³oºØ§K¬Ì¯à¤O¦b¦Ñ¹«©M¤ÑªÇ¹«ªº¸ÕÅ礤¤]ªí²{¥X¨Ó¡C§K¬Ì¤ÏÀ³ªº¨ë¿E©Ê¹ï¥¼P¬¡¤§¯S®í§Üì ( nonliving particulate antigens ) ¨Ã¨S¦³¨î¡A¹ï¤j¸z±ìµß¦Ó¨¥¡A¨Ï¥Îµ}ÄÀªº©e¤º·ç©Ô«~¨t°¨ªº¸£ª¢¬Ì] ( venezuelan equine encephalitis virus vaccine ) ¤]¦³¬Û¦üªº®ÄªG¡C
¡@¡@1973 ¦~ Spallholz ¤Î 1984 ¦~ Colnago µ¥¤H»{¬°¡A¦pªG¹}³¤¤§â°ª©ó±ÀÂ˶qªºÖ´ ( Se ) ²K¥[¤J¡A·í§@Àç¾iªº»Ý¨D¶q¡A«h¥i¥H¼W±jªì¯Å§K¬Ì¤ÏÀ³¡C³oºØµ²ªG¤D®Ú¾Ú§ÜÅé§Î¦¨²ÓMªº¼Æ¥Ø©M¦Ï¬õ¦å²y¾®¶°§ÜÅ骺¿@«×´ú©w¥X¨Óªº¡CµM¦Ó¡AÖ´ ( Se ) ªº¨ë¿E§@¥Î»P±J¥Dºû¥Í¯À E ªºÀç¾i¼Ð·ÇµLÃö¡C
¡@¡@²K¥[ºû¥Í¯À E ¥i¥H¨ë¿E§K¬Ì²y³J¥Õ G ( IgG ) ¦X¦¨¤§®ÄÀ³¡A¬Û¹ï¦aÖ´ ( Se ) ¥i¥H«P¶i§K¬Ì²y³J¥Õ M ( IgM ) ¥Í¦¨²ÓMªº¼W¥[¤Î IgM §ÜÅ骺¦X¦¨¼W¥[¡C¦Ó¥B¡A«Ü¦³½ìªº¬O·í¹}³¿@«×²K¥[¦Ü»Ý¨D¶qªº 10 ~ 30 ¿®É¡A®ÄªG³Ì¦n¡C¥i¬O¡A¹ï¨ä¥LºØÃþªº÷¨Å°Êª«¦Ó¨¥¡A¬O§_·|¤¤¬r¡A¨º´Nȱo°Óºe¡C
¡@
(¤C)ºò¢ ( stress ) »P§K¬Ì¤ÏÀ³
¡@¡@¥Ñ©óÂû°¦¦³©è§Ü¾D¨üªººØºØºò¢©M±N¹}®ÆÂà´«¦¨°ª«~½èªº¦×©M³J¤§¯à¤O¡A©Ò¥H®a¸V¨Æ·~¤´µM»]»]¤é¤W¡C¦Ó³\¦h¤£¦P§Î¦¡ªººò¢¹ï¹}¾iªº®a¸V¬O«Ü¤jªº§xÂZ¡C
¡@¡@1950 ¦~ Selye ¬ã¨s¥X¤@®M²z½×¡A¥Î¨Ó¸ÑÄÀ°Êª«¦³¾÷Åé¹ïºò¢ªºµ{«×»PºØÃþªº¤£¦P¤ÏÀ³±¡§Î¡C®Ú¾Ú³oÓ²z½×¡A¤@¨Ç³æ¤@ªººò¢¡A½Ñ¦p´H§NÀô¹Ò¡B¹}³¤¤³æ¤@Àç¾i¯Àªº³¡¥÷¯Ê¥F¡B©ÎªÌ¬O°Êª«¨t²Î¤Wªº§ïÅÜ©Ò¤Þ°_ªº»´·L¯e¯fª¬ªp¡A³Ìªì¤Þ°_¤@ÓÅå·W©Ê¤ÏÀ³ ( alarm reaction )¡A«á¨Ó´N¦ñÀHµÛ¤@Ó¾AÀ³©Ê¤ÏÀ³ ( adoptation reaction )¡A¥L§â³oºØ¹ïºò¢ªº¤ÏÀ³ºÙ¤§¬°¤@¯ë©Êªº¾AÀ³¯à¤Oºî¦X¯gª¬ ( General adaptation syndrome )¡C
¦Ó®Ú¾Ú 1964 ¦~ Von Faber ©Ò´£ªº¤pÂû¥NÁ¤§§ïÅÜ»Pºî¦X¯gª¬ªºÁp·Q¡G
(1)¸£¤U¸¢«e¸ ( anterior pituitary gland ) ªºªÎ¤j¡A¥i¯à¬O¥Ñ©óµÇ¤W¸¢¥Ö½è¯À ( adreno - corticotrophic hormone ( ACTH ) ªº¤Àªc¼W¥[¤§½t¬G¡C
(2)µÇŦ¸~¤j¡A°_¦]©ó¤º³¡ªºªÎ¤j¡C
(3)µÇŦªºÁx©T¾J´î¤Ö¡A»PµÇ¤W¸¢¥Ö½è¯À ( ACTH ) ªº¤Àªc¼W¥[¬O¦P®Éµo¥Íªº¡C
(4)²O¤Ú°h¤Æ¡C¤]´N¬O¹ï¥®¸V¨Ó»¡¡A¯Ý¸¢¡B·Æ¤óÅn¤ÎµÊŦªºµäÁY¬Oºò¢µo¥Í³Ì±Ó·Pªº«ü¼Ð¡C¦Ó¦¨¸V¤§·Æ¤óÅn®ø¥¢¡A¬O©Ê¸¢Ãþ©T¾Jªº¼vÅT¡C
(5)¥Õ¦å²y´`Àôªº§ïÅÜ¡C§Y¬O²O¤Ú²yªº´î¤Ö©M²§¶Ý©Ê²ÓM ( beterophils ) ªº¼W¥[¡C
(6)¦å¤¤ÂfÂc»Ä§t¶qªº¼W¥[¡C
(7)¥Íªø¿ð½w©ÎÅé«´î»´¡C
¡@¡@°²¦pºC©Êªººò¢¤£¬O¤Ó±j¯Pªº¸Ü¡A°Êª«±N¥i§¹¥þªº¾AÀ³¡A¦Ó¥B¥Íªø©Mµo¨|¨S¦³¤Ó¤j¤£¦P¡CµM¦Ó¡A°²¦p¦P®É¾D¨ü¨âºØºò¢¡A°Êª«±N·|Ãø¥H¾AÀ³¡CÁaµM¡A¨âÓ¦P®Éµo¥Íªººò¢¤£¤ñ³æ¤@ºò¢¨Ó±o±j¯Pªº±¡ªp¤U¡A¨ÌµM¥i¯à·|³y¦¨¦º¤`¡C
¡@¡@©Ò¥H®Ú¾Ú³oºØ²z½×¡A§Y¨Ï¹}³µo¥Í¥²»Ýºû¥Í¯À©ÎÓi°ò»Ä»´·L¯Ê¥F®É¡A°Êª«¤´¯à¬Û·í¥¿±`¦aµo¨|¥Íªø¡C
¡@¡@µM¦Ó¡A°²Y¤pÂû¥¿±Á{¥h¾AÀ³¤@ºØÀç¾i¤W¯Ê¥Fªººò¢®É¡A¬ðµM¶¡¾D¨ü¨ì²yÂίf©Î¨ä¥L¯e¯fªº«Iŧ¡A¨º»ò§Y¨Ï¨Ï¥ÎÀç¾i¨¬°÷ªº¹}³¡A¯e¯f¤]¥¼¹FÄY«P¦ºªº¤pÂû¡A¦¹®É¤]¥i¯à·|¤Þ°_¦º¤`¡C¯e¯f¬O¤@ºØºò¢¡AÀç¾iªº¯Ê¥F¬O¤@ºØºò¢¡B´H§N¡BµjÅË ( cramped )¡B¦Ç¹Ð¦h¡B¹}¾i¹L±K¡B³q·¡B»êż¡B¼éÀã©M¤£µÎ¾AªºÀô¹Ò±ø¥ó¤]³£¬Oºò¢¡F±µºØ¬Ì]¡B°Å¼L·|µo¥Íºò¢¡FÃĪ«³B²z¤]¥i¯à²£¥Íºò¢¡F²§±`¾¸µ¡B¾E²¾¡BÂû°¦ªº§ì®·¡B¸ËÄx¤Î¸ü¹B¤]³£·|µo¥Íºò¢¡C¦b¤U¦C¨âºØ¾÷¨î³~®|¤¤¡AÀô¹Ò¦]¤l¥i¯à¼vÅT®a¸Vªº§K¬Ì¤ÏÀ³¡C
(a)·í¶ÀÄT¬r¯À©M¨ä¥LÃĪ«¤Þ°_ªº¤¤¬rµo¥Í®É¡A±q¼ß²ÓM¡B²O¤Ú²ÓM©M¥¨¾½²ÓM©Ò´£¨Ñ§ÜÅé¡A²ÓM¤¤¶¡©Ê§K¬Ì©M§Ü쪺¹Lµ{¤¤µo¥Íª½±µªýê·|¤Þ°_ªº¨ß¬Ì§í¨î§@¥Î¡C¬r¯À¤]¥i¯à¸ò«D¯S²§¦a´£°ª¤ÏÀ³¤§¦¨¤À ( ¦p²§¶Ý©Ê²ÓM¡B¸ÉÅé©M¨Å¨x½Å¯À ( lactoferrin ) ) °_§@¥Î¡C
(b)Àô¹Ò¦]¤l¥i¯à¸g¥ÑµÇ¤W¸¢¯À§@¥Î¡C¤]´N¬OÂǵۨë¿EµÇ¤W¸¢¥Ö½è¯À ( ACTH ) ªº¤Àªc»P¦X¦¨¡A¨Ó§í¨î ( suppress ) ©Î·»¸Ñ ( lyse ) §ÜÅé§Î¦¨²ÓM¡C¦Ó§N¡B¼ö¡B·l¶Ë©M¹L«×¾ÖÀ½¦ü¥G´N¬O¥H³o±ø³~®|¨Ó§í¨î§K¬Ì§@¥Î¡C
1.¼öºò¢
¦b¼öºò¢¤U¡A®a¸V·|¨³³t¦a¤W¤ÉÅé·Å¡B§ïÅܦ夤¹q¸Ñ½è«¬ºA¤Î¤ß»P¦åºÞªº²§±`¡C
¡@¡@1979 ¦~ Cheville µo²{¦b¸ÕÅ礤¡A«æÆJªº¼öºò¢¨Ï¤õÂû¦å¤¤¹[§t¶q«D±`©úÅã¦a¤U°¡C¦Ó 1973 ¦~ Kohne µ¥¤H¤]³ø§i¤F¼öºò¢¤U¡A¦åÁÞ·|³Q´£°ª¡C©Ò¥H«Øij¦b¼öºò¢¤U¨î±Ä¹¶q¡A±N¥i¥H´£°ª¦s¬¡²v¡C
¡@¡@¸ÕÅçÅã¥Ü¤pÂû¦bÀô¹Ò·Å«×°ªªº®ÉÔ¡A¦bªì¯Å§Üì¨ë¿E©|¥¼¶}©l¤§«e¡A¤w¸g¤Þ°_¤Fªì¯Å§K¬Ì¤ÏÀ³¾D¨üªý¼¸¡C¦¹¥~¡A¼öºò¢¤]¤j¤j¦a°§C¤w¸g¦s¦bªº§ÜÅé¿@«×¡C³o¦ü¥G»¡©ú¦]¼ö©Ò»¤µoªº§K¬Ì§í¨î§@¥Î¡A¤]¶¡±µ¦a¼vÅT¨ìµÇ¤W¸¢¥Ö½è²ÓMªº¤Àªc§@¥Î¡C
¡@¡@¨º´N¬O»¡¡A¦]¼öºò¢¤Þ°_ªº¦å¼ß¤¤¥Ö½è¹}ଶqªº´£°ª¡A¼vÅT¤F²O¤Ú²ÓMªº§í¨î©Î¯}Ãa¡CMetyrapone ¬O¤@ºØµÇ¤W¸¢¥Ö½èÃþ©T¾J¦X¦¨ªºªýÂ_¾¯¡A¥i¥H´î¤Ö¼ö¤ÎµÇ¤W¸¢¥Ö½è¯À ( ACTH ) ªº§K¬Ì§í¨î®ÄÀ³¡C
2.§Nºò¢
¡@¡@Fortier ©M De Groot »{¬°µÇ¤W¸¢ªº¬¡©Ê¡A¸g±`³Q·í¦¨µûÂ_¥Í²zºò¢ªº¼Ð·Ç¡Cªø´Á¼ÉÅS¦b§NÀô¹Ò¤U¡A·|«ÜÅãµÛ¦a¼W¥[§ÜÅé»ù¡Cµu®É¶¡¼ÉÅS¦b§NÀô¹Ò 2 ©Î 4 ¦¸¡A¦ñÀHµÛ§Ü쪺ª`®g¡A·|´£°ª¾®¶°¯À©Î·»¦å¯Àªº¤ÏÀ³¯à¤O¡C³o¨Ç¸ê®Æ«ü¥X¡A§ÜÅé»ùªº´£°ª»P´H§Nª¬ºA¤Î§Üìª`®gªº®É¶¡¦³±K¤ÁÃö«Y¡A¾Ú»¡´H§NªºÀô¹Ò·|¨ë¿E¤pÂû¥Òª¬¸¢ªº¬¡©Ê¡A¦Ó·Å©MªºÀô¹Ò«o·|§í¨î¥¦ªº§@¥Î¡C
3.Âû¸s±K«×ºò¢
¡@¡@°ª±K«×¹}¾i¤UªºÂû¸s¡A®e©ö¤Þ°_¯e¯fµo¥Íªº¼W¥[¡C¾ÖÀ½ªº¼vÅT¡A³y¦¨Âû¸s¤¬¬Û¶Ç¬V¨Ã¤£·|«Ü©úÅã¡A¦ý«o¥i¥H¾ÉP¤ô¡B¹ª«©Î¹Ô®Æªº¦Ã¬V¡C¦Ó¥B¦b®a¸Vªº¥Í²z¤ÏÀ³¤è±¡A¾ÖÀ½¦³¤@Óª½±µªº¼vÅT¡A¨º´N¬O©Ò¿×ªº¡§ªÀ·|ºò¢ ( social stress )¡¨¡C³oºØªÀ·|ºò¢¯g«á¡A¨üµÇ¤W¸¢¥Ö½è¯À¤Àªcªº¼vÅT¡C
¡@¡@Âû¸s±K«×ºò¢¦ü¥G¹ï¶Ç¬V©Ê¤Î§K¬Ì©Ê¦³ª½±µªº¼vÅT¡C1971 ¦~ Gross ©M Colmano »{¬°¡A¤pÂûºû«ù¦b«D±`¨}¦nªºªÀ·|Àô¹Ò¤U¡A¹ï¯f¬r©Ê¶Ç¬Vªº·P¨ü¤O¤ñ¹ï²Óµß©Ê¶Ç¬Vªº·P¨ü¤On¨Ó±o±j¯P¡C
¥L̶i¦æ¤@³s¦êªº¸ÕÅç¡A±o¨ì¤F¤@¨Çµ²ªG±À½×¡G
(1)¦å¼ß¤¤¥Ö½èପº¿@«×´£°ª»P¤pÂû¹ï¤j¸z±ìµßªº©è§Ü¤O¡A¦³¥¿±¼vÅTªºÃö«Y¦s¦b¡C
(2)¤pÂû¹ê¬I¥Ö½èପºª`®g¡A¥i¥H¾ÉP¶Ç¬V¤j¸z±ìµßªº©è§Ü¤O¼W¥[¡C
(3)¤Æ¾Çª«½èªýº¢µÇ¤W¸¢¥Ö½è¯Àªº²£¥Í¡A·|¤Þ°_¹ï¯f¬r©Ê¶Ç¬Vªº·P¨ü¤O¼W±j¡A¦Ó°§C¹ï¤j¸z±ìµß¶Ç¬Vªº·P¨ü¤O¡C
(4)¨ã¦³¹ïºò¢²£¥Í§C¦å¼ß¥Ö½èତÏÀ³©Ê©M¿@«×ªº¤pÂû«~¨t¡A¬O¹ï¤j¸z±ìµß¶Ç¬V¦³¸û±j¯Pªº·P¨ü¤O¡A¦ý¬O«o¥i¥H§ó¦³®Ä¦a©è§Ü°¨¥ß§J¯f ( Marek's disease ) ©MÅð¼ßµß¯g ( Mycoplasma gallisepticum )¡C
4.ºû¥Í¯À E ªº¯Ê¥F
¡@¡@¯S®íºû¥Í¯Àªº¯Ê¥F¡A°¸¦Ó·|³Q°²©w¬O³y¦¨¶Ç¬V©Ê¯e¯fªº¦]¯À¡CÁöµM¡A¦³®ÉÔ·|»¡¤Î§K¬Ì¨t²Î¹ï¤ÏÀ³ªº¥¢±Ñ¡A¦ý¬O¤jÅé¦Ó¨¥¡A»PÅܧó²ÓM¥NÁ¦³Ãöªº¤£©ú½T¾÷¨î¡A¦b´£°ª·P¨ü¤O¤è±³q±`¬O«Ü½ÆÂøªº¡C¹ï¤pÂû¨Ó»¡¡Aºû¥Í¯À E ¯Ê¥Fªº¼vÅT¬OÂÇ®a¸V¸£¯áÅ誢¯f¬r ( avian encephalomelitis virus ) ©Ò»¤µoªº¦º¤`²{¶H¡C
¡@¡@Cheville ©M Monlux «ü¥X¡Aºû¥Í¯À E ¯Ê¥Fªº¤pÂû¤ñ¹ï·Ó²Õªº¤pÂû¹ï®a¸V¸£¯áÅ誢¯f¬r ( AE Virus ) ¨ã¦³µy·L®t¤@ÂIªº·P¨ü¤O¡CµM¦Ó¡A¹ï²Óµß©Ê¶Ç¬Vªº·P¨ü¤O«h¦³¬Û¤Ïªº®ÄªG¡C¹}³¤¤²K¥[ºû¥Í¯À E ( ©Î·L¥Í¯À A ) ¥i¥H°§C¦]¤j¸z±ìµß©Ò»¤µoªº¦º¤`²v¡C³o®ÄÀ³¦³§U©ó§ÜÅé²£¥Íªº¼W¥[¡A©M¼W¥[¥¨¾½²ÓMªº¦X¦¨¡C´N¸ÕÅç¤W¨Ó»¡¡A·í¥ÀÂûÁý¹}ºû¥Í¯À E ®É¡A·|´£°ª¤pÂû¦å¼ß¤¤¸g¥Ñ³Q°Ê¹B¿éªº§ÜÅé¿@«×¡C
¡@
¹}®ÆÀç¾iÂø»x²Ä¤¥U¦Xq¥»
1989¦~¤¸¤ë¸¹¦Ü1989¦~²Ä¤»´Á
¤K¤E¦~¡D²Ä¤»´Á ( 22 ~ 32 )
Copyright © 1998 Z¸s®n¯bªªºô.
¥»ºô¯¸¹Ï¤å«YÄÝZ¸s®n¦³¤½¥q¡A¤º¤å¤§ª©Åv¬°¸ÓÂø»xªÀ©Ò
¦³¡A«D¸g¥»¤½¥q¤Î¸ÓÂø»xªÀ¥¿¦¡®Ñ±¦P·N¡A¤£±o±N¥þ³¡©Î³¡¤À¤º®e¡A
Âà¸ü©ó¥ô¦ó§Î¦¡´CÅé
¡° ³Ì¨Î¸ÑªR«× 800x600
Copyright © 1998
MiobufferCo., Ltd. All rights reserved.
Unauthorized copying and reproduction is prohibited. All trademarks property of their
respective holders.